Mumbai : Ipca Laboratories has been conferred with the prestigious “Clinical and Research Excellence (CARE) Awards”, 2016 in the category “Clinical Trial Result of the Year’ for its clinical trial “Efficacy of low-dose Chlorthalidone and Hydrochlorothiazide as assessed by 24-h Ambulatory Blood Pressure Monitoring”.
The category of “Clinical Trial Result of the Year” award was to honor the clinical trial that had greatest impact in 2015 and leads to an advance in healthcare.
This global award was organized by Informa, one of the largest publishers in the pharmaceutical field.
This trial was published in February 2016 issue of prestigious journal “Journal of the American College of Cardiology”, the best read cardiovascular journal worldwide.
Ipca Laboratories Ltd is currently trading at Rs. 495, down by Rs. 1.25 or 0.25% from its previous closing of Rs. 496.25 on the BSE.
The scrip opened at Rs. 496 and has touched a high and low of Rs. 503.95 and Rs. 493 respectively. So far 91835 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 6262.68 crore.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 888 on 19-Aug-2015 and a 52 week low of Rs. 480 on 08-Apr-2016. Last one week high and low of the scrip stood at Rs. 506.45 and Rs. 488 respectively.
The promoters holding in the company stood at 45.89 % while Institutions and Non-Institutions held 38.24 % and 15.86 % respectively.
